Clopidogrel Bisulfate Tablet, Film Coated
Product Images NDC 63187-639

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel Bisulfate (NDC 63187-639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1 (Clopidogrel Fig1)

This appears to be a chart displaying the effect of co-administered PPL on the active metabolite AUC for various drugs including Dexlansoprazole, Lansoprazole, Pantoprazole, and Omeprazole. The chart includes mean values and 90% confidence intervals. The numbers on the bottom likely represent time intervals or doses.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

The given text provides information on the cumulative event rate of cardiovascular death, myocardial infarction, and stroke. The event rate is presented as a percentage and is compared between two treatment options i.e. Placebo and Clopidogrel bisulfate- indicating the efficacy of each treatment in preventing the three fatal events. The data is further presented over a time period of several months with the use of other standard therapies.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

This appears to be a table showing the percentage of events related to different treatments or conditions. The table seems to show data related to different groups such as age range, race, and previous treatments. Specific information such as the number of events and percentage for each group is also included. There is mention of beta-blocker and an ACEL treatment, but it is unclear what these are referring to. A note at the bottom mentions the use of other standard therapies. Overall, without more context, it is difficult to interpret this data or provide a more precise description.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

This appears to be a table or a report related to a medical study. It includes data on the number of deaths and the percentage of deaths among patients taking Placebo and Cloptdogrel. The table shows that there were 1845 deaths (8.1%) in the Placebo group and 1726 deaths (75%) in the Cloptdogrel group. It also mentions a proportional risk reduction of 75% with a p-value of 0.03. The last row of the table shows the number of days since randomization, up to 25 days. It is unclear what the terms "e doad", "betoro", "tiet", and "discharge" represent.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

FDA Label Image

Figure6 (Clopidogrel Fig6)

FDA Label Image

Figure7 (Clopidogrel Fig7)

FDA Label Image

Figure8 (Clopidogrel Fig8)

FDA Label Image

63187-639-30 (Clopidogrel Fig9)

This is a description of Clopidogrel 75mg tablets from ScieGen Pharmaceuticals, Inc. They are pink, round, and biconvex with the letters SG and 124 on one side. Each tablet contains 97.875mg equivalent to 75mg of clopidogrel base. They come in a bottle of 30 tablets with the medication guide provided separately for each patient. The tablets are RX only and should be stored at 20°-25°C away from the children's reach. There are several lots with the same SN# MASTER and expiring on 00/00/00. The tablets have been relabeled by Proficient Rx LP in Thousand Oaks, CA.*

FDA Label Image

Structure (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.